BIT:1REGN - Euronext Milan - US75886F1075 - Common Stock - Currency: EUR
BIT:1REGN (5/9/2025, 7:00:00 PM)
481.5
-53.7 (-10.03%)
The current stock price of 1REGN.MI is 481.5 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 18.18 | 297.54B | ||
AMG.DE | AMGEN INC | 12.96 | 130.25B | ||
1GILD.MI | GILEAD SCIENCES INC | 13.27 | 115.15B | ||
GIS.DE | GILEAD SCIENCES INC | 13.07 | 113.46B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 100.74B | ||
ARGX.BR | ARGENX SE | 101.39 | 29.84B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.71B | ||
IDP.DE | BIOGEN INC | 7.71 | 16.10B | ||
1MRNA.MI | MODERNA INC | N/A | 8.90B | ||
0QF.DE | MODERNA INC | N/A | 8.88B | ||
BIO.DE | BIOTEST AG | 65.54 | 1.69B | ||
GLPG.AS | GALAPAGOS NV | N/A | 1.52B |
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 13,450 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
REGENERON PHARMACEUTICALS
777 Old Saw Mill River Road
Tarrytown NEW YORK US
Employees: 13926
Phone: 17813705000
The current stock price of 1REGN.MI is 481.5 EUR. The price decreased by -10.03% in the last trading session.
The exchange symbol of REGENERON PHARMACEUTICALS is 1REGN and it is listed on the Euronext Milan exchange.
1REGN.MI stock is listed on the Euronext Milan exchange.
34 analysts have analysed 1REGN.MI and the average price target is 976.66 EUR. This implies a price increase of 102.84% is expected in the next year compared to the current price of 481.5. Check the REGENERON PHARMACEUTICALS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
REGENERON PHARMACEUTICALS (1REGN.MI) has a market capitalization of 52.64B EUR. This makes 1REGN.MI a Large Cap stock.
REGENERON PHARMACEUTICALS (1REGN.MI) currently has 13926 employees.
The Revenue of REGENERON PHARMACEUTICALS (1REGN.MI) is expected to grow by 3.48% in the next year. Check the estimates tab for more information on the 1REGN.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
REGENERON PHARMACEUTICALS (1REGN.MI) has a dividend yield of 0.52%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of 1REGN.MI dividend history, reliability and sustainability.
REGENERON PHARMACEUTICALS (1REGN.MI) will report earnings on 2025-04-30, before the market open.
The PE ratio for REGENERON PHARMACEUTICALS (1REGN.MI) is 11.72. This is based on the reported non-GAAP earnings per share of 41.09 and the current share price of 481.5 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1REGN.MI.
ChartMill assigns a technical rating of 2 / 10 to 1REGN.MI.
ChartMill assigns a fundamental rating of 7 / 10 to 1REGN.MI. 1REGN.MI scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Over the last trailing twelve months 1REGN.MI reported a non-GAAP Earnings per Share(EPS) of 41.09. The EPS increased by 4.25% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 31.07% | ||
ROA | 11.69% | ||
ROE | 15.03% | ||
Debt/Equity | 0.09 |
ChartMill assigns a Buy % Consensus number of 78% to 1REGN.MI. The Buy consensus is the average rating of analysts ratings from 34 analysts.
For the next year, analysts expect an EPS growth of -4.81% and a revenue growth 3.48% for 1REGN.MI